532649 Stock Overview
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally.
Nectar Lifesciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹22.80|
|52 Week High||₹38.95|
|52 Week Low||₹20.75|
|1 Month Change||-0.65%|
|3 Month Change||-1.30%|
|1 Year Change||-22.97%|
|3 Year Change||68.39%|
|5 Year Change||-14.45%|
|Change since IPO||-11.88%|
Recent News & Updates
|532649||IN Pharmaceuticals||IN Market|
Return vs Industry: 532649 underperformed the Indian Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 532649 underperformed the Indian Market which returned 0.5% over the past year.
|532649 Average Weekly Movement||4.4%|
|Pharmaceuticals Industry Average Movement||5.1%|
|Market Average Movement||5.8%|
|10% most volatile stocks in IN Market||9.1%|
|10% least volatile stocks in IN Market||3.7%|
Stable Share Price: 532649 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 532649's weekly volatility (4%) has been stable over the past year.
About the Company
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.
Nectar Lifesciences Fundamentals Summary
|532649 fundamental statistics|
Is 532649 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|532649 income statement (TTM)|
|Cost of Revenue||₹12.28b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.21|
|Net Profit Margin||1.61%|
How did 532649 perform over the long term?See historical performance and comparison
Is 532649 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 532649?
Other financial metrics that can be useful for relative valuation.
|What is 532649's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 532649's PE Ratio compare to its peers?
|532649 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
506414 Fermenta Biotech
506197 Bliss GVS Pharma
531633 Lincoln Pharmaceuticals
541400 ZIM Laboratories
532649 Nectar Lifesciences
Price-To-Earnings vs Peers: 532649 is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (29.2x).
Price to Earnings Ratio vs Industry
How does 532649's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 532649 is good value based on its Price-To-Earnings Ratio (18.8x) compared to the Indian Pharmaceuticals industry average (23.5x)
Price to Earnings Ratio vs Fair Ratio
What is 532649's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||18.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532649's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 532649 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 532649 (₹22.8) is trading below our estimate of fair value (₹46.53)
Significantly Below Fair Value: 532649 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Nectar Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nectar Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Nectar Lifesciences is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Nectar Lifesciences competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Nectar Lifesciences performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 532649 has high quality earnings.
Growing Profit Margin: 532649 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 532649's earnings have declined by 56.2% per year over the past 5 years.
Accelerating Growth: 532649 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 532649 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.1%).
Return on Equity
High ROE: 532649's Return on Equity (2.5%) is considered low.
Discover strong past performing companies
How is Nectar Lifesciences's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 532649's short term assets (₹13.5B) exceed its short term liabilities (₹10.0B).
Long Term Liabilities: 532649's short term assets (₹13.5B) exceed its long term liabilities (₹3.0B).
Debt to Equity History and Analysis
Debt Level: 532649's net debt to equity ratio (77.4%) is considered high.
Reducing Debt: 532649's debt to equity ratio has reduced from 88% to 79% over the past 5 years.
Debt Coverage: 532649's debt is not well covered by operating cash flow (11%).
Interest Coverage: 532649's interest payments on its debt are not well covered by EBIT (1.4x coverage).
Discover healthy companies
What is Nectar Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 532649's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 532649's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 532649's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 532649's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 532649 is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 532649 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amit Chadah (52 yo)
Mr. Amit Chadah serves as the Chief Executive Officer of Nectar Lifesciences Limited since October 30, 2020. He was President of Business Development until October 30, 2020. He has joined the Nectar Lifesc...
Experienced Management: 532649's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: 532649's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Nectar Lifesciences Limited's employee growth, exchange listings and data sources
- Name: Nectar Lifesciences Limited
- Ticker: 532649
- Exchange: BSE
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹5.113b
- Shares outstanding: 224.26m
- Website: https://www.neclife.com
Number of Employees
- Nectar Lifesciences Limited
- SCO 38-39
- Sector 9d
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|532649||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jul 2005|
|NECLIFE||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Jul 2005|
|NECLF||BDL (Bourse de Luxembourg)||GDR EACH REPR 1 ORD INR1 REG'S'||LU||USD||Mar 2010|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/25 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.